Abstract Number: 2487 • ACR Convergence 2025
Cardiovascular and venous thromboembolic events in systemic sclerosis: Epidemiological analysis of the Clinical Practice Research Datalink
Background/Purpose: Cardiovascular disease is a leading cause of mortality in systemic sclerosis (SSc). We investigated the association between SSc and the occurrence of both cardiovascular…Abstract Number: 2363 • ACR Convergence 2025
Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), yet the comparative safety of…Abstract Number: 2317 • ACR Convergence 2025
Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
Background/Purpose: Patients with PsA have an elevated risk of cardiovascular (CV) disease. We assessed whether specific PsA features may predict CV events among PsA patients.Methods:…Abstract Number: 2256 • ACR Convergence 2025
Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study
Background/Purpose: The increased risk of cardiovascular morbidity and mortality with rheumatoid arthritis has been increasingly acknowledged over the past decades. Cardiovascular disease risk management for…Abstract Number: 2024 • ACR Convergence 2025
Racial Disparities in Outcomes Among Patients With Neuromyelitis Optica: A Global Population-Based Study
Background/Purpose: Neuromyelitis optica (NMO) is a rare, chronic, immune-mediated, demyelinating disorder predominantly affecting the optic nerve and spinal cord. Despite increasing awareness, racial disparities in…Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…Abstract Number: 0729 • ACR Convergence 2025
ANCA-associated vasculitis – does the type matter?
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a heterogeneous group of rare autoimmune disorders that cause inflammation of blood vessels with various manifestations. Our study…Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…Abstract Number: 0436 • ACR Convergence 2025
Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
Background/Purpose: Patients with rheumatic disease have an increased risk for thrombotic events and major adverse cardiac events (MACE) due to systemic inflammation. Bleeding time is…Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…Abstract Number: 0174 • ACR Convergence 2024
A Nationwide Analysis of Gender and Racial Disparities in Patients with Systemic Sclerosis and Acute Coronary Syndrome
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune condition characterized by widespread skin fibrosis and/or end-organ damage. Previous studies have reported variable outcomes of the disease…Abstract Number: 1981 • ACR Convergence 2024
Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments
Background/Purpose: This study aims to evaluate the risk of major cardiovascular events (MACE) associated with common rheumatology medications.Methods: We conducted a retrospective pharmacovigilance analysis using…Abstract Number: 2009 • ACR Convergence 2024
Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…Abstract Number: 2631 • ACR Convergence 2024
Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study
Background/Purpose: There is evidence of an increased risk of cardiovascular disease in several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In primary…Abstract Number: 0248 • ACR Convergence 2023
In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout
Background/Purpose: Patients with gout are at increased risk of acute myocardial infarction (AMI). However, the clinical course, secondary prophylaxis and mortality after AMI has not…
ACR Meeting Abstracts